01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
02 July 2021 - A snapshot of the news that broke today, featuring Catapult (ASX:CAT), CIMIC (ASX:CIM) & Westpac (WBC).
02 Jul 2021 - I cover Wall St's performance as they continued their momentum to start the 2nd half of the year. Jobless claims dropped ahead of labour figures. Oil prices boost markets while OPEC continues their talks on supply which helped European markets as Prime Minister Boris Johnson makes an upbeat statement. Asian markets responded to weak manufacturing figures. Yesterday the ASX 200 ended the day on a backfoot. Macquarie cuts Reece's (ASX:REH) rating. Six companies pencilled...
02 Jul 2021 - I cover Wall St's performance as they continued their momentum to start the 2nd half of the year. Jobless claims dropped ahead of labour figures. Oil prices boost markets while OPEC continues their talks on supply which helped European markets as Prime Minister Boris Johnson makes an upbeat statement. Asian markets responded to weak manufacturing figures. Yesterday the ASX 200 ended the day on a backfoot. Macquarie cuts Reece's (ASX:REH) rating. Six companies pencilled...
01 Jul 2021 - A snapshot of the news that broke today featuring Westpac (ASX:WBC), Worley (ASX:WOR), Seek (ASX:SEK) and Lendlease (ASX:LLC).
01 Jul 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results from the company's study of its NYX-PCSK9i cholesterol-lowering compound.
01 Jul 2021 - In this report, I cover Wall St's mixed performance as US shares closed off the first half of 2021. Microchips take the spotlight in recent times and why. A wrap-up of the ASX 200 on EOFY and YTD performance. Why Morgans downgraded Collins Foods (ASX:CKF). Big day of economic news today.
01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
